CAS: 606-04-2; 8-Bromo-1,3-Dimethyl-3,7-Dihydro-1H-Purine-2,6-Dione--2-Amino-2-Methylpropan-1-Ol (1/1)

该化合物是一种化学化合物,主要用作各种药品配方中的二分泌剂,是Xanthine类的溴化衍生物,以其能够促进排泄体中的水和电解液而闻名,有助于减轻与水保留有关的症状.Pamabrom通常与场外药物中的其他活性成分结合使用,目的是缓解月经不适和浮肿.该化合物的特点是水溶性相对较低,能够影响其生物利用率和功效.此外,Pamabrom展示了一种中度的安全特征,尽管潜在的副作用可能包括胃肠扰动和敏感个人过敏反应.其行动机制包括抑制钠和水的肾管再吸附,导致尿液产量增加.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-2008287407-A1
    优先权日:2003-12-10
    标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
    发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

    专利号:CN-101678118-A
    优先权日:2006-10-05
    标 题:Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    专利号:CN-104800862-A
    优先权日:2006-10-05
    标题 :Efficient synthesis, compositions and uses of chelators for nuclear imaging and radiotherapy
    乐普药业股份有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.lepupharmaceuticals.com
    电话: 010-80123757,80123758👤
    📞乐普药业股份有限公司 ⚠️参考联系方式

    销售电话:010-80123757,80123758
    邮箱:shuaike@shuaike.com.cn
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Abdelaleem EA, Naguib IA, Hassan ES, Ali NW. HPTLC and RP-HPLC methods for simultaneous determination of Paracetamol and Pamabrom in presence of their potential impurities. J Pharm Biomed Anal. 2015 Oct 10;114:22-7. doi: 10.1016/j.jpba.2015.04.043. Epub 2015 May 8.
    3: Tan DS, Sklar GE. Erythema multiforme secondary to dimenhydrinate in a patient with previous similar reactions to pamabrom. Ann Pharmacother. 2014 Mar;48(3):425-8. doi: 10.1177/1060028013518728. Epub 2014 Jan 6. doi: 10.4137/ACI.S12349. eCollection 2013.
    5: Lee S, Yang Y, Fishman D, Banaszak Holl MM, Hong S. Epithelial-mesenchymal transition enhances nanoscale actin filament dynamics of ovarian cancer cells. J Phys Chem B. 2013 Aug 8;117(31):9233-40. doi: 10.1021/jp4055186. Epub 2013 Jul 26.

    合成参考文献


    参考文献:10.1007/s00204-020-02882-4
    摘要:Oda S, Uchida Y, Aleo MD, Koza-Taylor PH, Matsui Y, Hizue M, Marroquin LD, Whritenour J, Uchida E, Yokoi T. An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149–68. doi: 10.1007/s00204-020-02882-4.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知